Talk:Pablo Legorreta
| This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||
| ||||||||
.svg){kind=small} | Daily pageviews of this article
A graph should have been displayed here but graphs are temporarily disabled. Until they are enabled again, visit the interactive graph at pageviews.wmcloud.org |
Possible Future Citations to be Used[edit]
The Private Equity Firm That Quietly Profits on Top-Selling Drugs - The New York Times (nytimes.com) https://www.forbes.com/sites/nathanvardi/2020/06/12/meet-the-secretive-wall-street-investor-with-the-billion-dollar-medicine-cabinet/ Brothers Make Billions From Ex-Merger Banker’s Pharma Firm - Bloomberg Moderna goes on the patent offensive; Pablo Legorreta doubles down; Is a biotech recovery on the way?; and more – Endpoints News (endpts.com) Pablo Legorreta | The New York Academy of Sciences (nyas.org) Tonyrexlibidine (talk) 23:41, 29 July 2023 (UTC)